A Study to Investigate the Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone in Patients Receiving Concomitant Chemo-radiotherapy With Weekly Cisplatin for at Least Five Weeks
Overview
- Phase
- Phase 2
- Sponsor
- Christina Ruhlmann
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Safety of weekly administration of Akynzeo measured by incidence of treatment-emergent adverse events
Overview
Brief Summary
This is a multicentre, single-arm, phase II study to investigate the safety and antiemetic efficacy of Akynzeo (a fixed dose combination of palonosetron and netupitant) plus dexamethasone in patients receiving concomitant chemo-radiotherapy with weekly cisplatin for at least five weeks.
Detailed Description
Akynzeo contains a combination of the neurokinin-1 receptor antagonist netupitant and the serotonin receptor antagonist palonosetron. Akynzeo is approved as antiemetic prophylaxis in patients receiving high emetogenic chemotherapy e.g. high dose cisplatin administered every three weeks.
From a previous clinical trial (GAND-emesis trial) we know that patients receiving radiotherapy and concomitant weekly cisplatin 40 mg/m2 are better protected against nausea and vomiting when a triplet antiemetic prophylaxis (neurokinin-1 receptor antagonist, serotonin receptor antagonist, and corticosteroid) is applied.
In the Akynzeo phase III clinical trials, Akynzeo was administered every three weeks. The neurokinin-1 receptor antagonist, netupitant, has a long plasma half-life (approx. 90 hours), and theoretically the drug could accumulate when administered on a weekly basis.
The DANGER-emesis trial is designed to collect safety and efficacy data in patients receiving Akynzeo weekly as antiemetic prophylaxis in combination with dexamethasone in patients treated for cervical cancer with radiotherapy and concomitant weekly cisplatin 40 mg/m2.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Supportive Care
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •The patient has a diagnosis of cervical cancer.
- •The patient understands the nature and purpose of this study and the study procedures and has signed informed consent.
- •The patient is aged ≥ 18 years.
- •The patient must be both chemo- and radiotherapy (RT) naïve. NB: previously low voltage RT or electron RT for non-melanoma skin cancers is allowed.
- •The patient is scheduled to receive fractionated radiotherapy and concomitant weekly cisplatin at a dose of ≥ 40 mg/m2 for at least five weeks.
- •Brachy therapy is scheduled to be initiated after the third cycle of weekly cisplatin, and preferentially after the fifth week of treatment.
- •Chemotherapy with an emetic risk potential of minimal or mild (up to 30%) is allowed on days 1-4 (see ref. 14).
- •The patient has a WHO Performance Status of ≤
- •Hematologic and metabolic status must be adequate for receiving weekly cisplatin in a dose of ≥ 40 mg/m2, and meet the following criteria:
- •Total neutrophils ≥ 1500/mm3 (Standard units : ≥1.5 x 109/L)
Exclusion Criteria
- •The patient has a current malignant diagnosis other than cervical cancer, with exception of non-melanoma skin cancers.
- •The patient is pregnant or lactating.
- •The patient has experienced emesis (i.e., vomiting and/or retching) or clinically significant nausea (defined as nausea graded as moderate or severe) in the 24 hours preceding the first dose of study medication.
- •The patient has a history active peptic ulcer disease, gastrointestinal obstruction, gastrointestinal carcinoma, increased intracranial pressure, hypercalcemia, or any uncontrolled medical condition (other than malignancy) which in the opinion of the Investigator may confound the results of the study, represent another potential etiology for emesis and nausea (other than CINV/RINV) or pose an unwarranted risk to the patient.
- •The patient has a known hypersensitivity or contraindication to palonosetron, another 5-HT3 receptor antagonist, dexamethasone, or netupitant.
- •The patient has previously received an NK1 receptor antagonist.
- •The patient has received an investigational drug in the previous 30 days or is scheduled to receive any investigational drug during the study period.
- •The patient has taken/received any medication of moderate or high emetogenic potential within the 48 hours prior to the first dose of study medications. Opiate drugs for cancer pain will be permitted if the patient has been on a stable dose and has not experienced emesis or clinically significant nausea from the narcotics in the 24 hours preceding the first dose of study medication.
- •The patient has taken/received any medication with known or potential antiemetic activity within the 24-hour period prior to receiving study drugs. This includes, but is not limited to:
- •5-HT3 receptor antagonists (e.g., ondansetron, granisetron, dolasetron, tropisetron, ramosetron). Palonosetron is not permitted within 7 days prior to receiving study drugs.
Arms & Interventions
Akynzeo plus dexamethasone
Akynzeo (capsule 300mg/0.5mg) Day 1 plus dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 to be administered weekly for five weeks.
Intervention: Akynzeo (Drug)
Akynzeo plus dexamethasone
Akynzeo (capsule 300mg/0.5mg) Day 1 plus dexamethasone 12 mg Day 1, 8 mg Day 2-3, and 4 mg Day 4 to be administered weekly for five weeks.
Intervention: Dexamethasone (Drug)
Outcomes
Primary Outcomes
Safety of weekly administration of Akynzeo measured by incidence of treatment-emergent adverse events
Time Frame: Five weeks.
Measurement of incidence of treatment-emergent adverse events.
Efficacy of weekly administration of Akynzeo measured by incidence of nausea and vomiting and use of rescue antiemetics
Time Frame: Five weeks.
Measurement of incidence of nausea and vomiting and use of rescue antiemetics.
Secondary Outcomes
- Complete response in terms of the proportion of subjects with complete response(Five days and five weeks.)
- No significant nausea in terms of the proportion of subjects with no significant nausea(Five days and five weeks.)
- No nausea in terms of the proportion of subjects with no nausea(Five days and five weeks.)
- Time to first emetic episode(Five weeks.)
Investigators
Christina Ruhlmann
Principal investigator
Odense University Hospital